ClinicalTrials.gg
RecruitingNCT06100289Updated Aug 3, 2026

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

A Phase 3 interventional study of Vedolizumab IV and Vedolizumab SC in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Recruiting at 54 sites in 16 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.

Planned enrollment
23rd of 38
70 · median 110
Started
2025
with 3 others
Phase 3
14 of 38
3 open now
Registered
32nd of 38
by date
Lead sponsor
22 of 38
Takeda

Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 23rd largest by planned enrollment, is one of 4 that started in 2025, is one of 14 in phase 3, and was the 32nd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing vedolizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC).

The participants will be treated with vedolizumab for up to 34 weeks.

During the study, participants will visit their study clinic several times.

Read the detailed description

The drug being tested in this study is vedolizumab. Vedolizumab is being tested to treat pediatric participants with moderate to severe active UC or CD who achieved clinical response following open-label vedolizumab intravenous (IV) therapy. The study will look at the pharmacokinetics, safety, and immunogenicity of vedolizumab.

The study will enroll approximately 70 patients. During the Induction Period participants will receive 3 doses of vedolizumab IV infusion at Day 1, Week 2, and Week 6 based on their weight at Baseline as:

  • Participants ≥30 kilograms (kg), Vedolizumab (High Dose)
  • Participants >15 to \<30 kg, Vedolizumab (Medium Dose)
  • Participants ≥10 to ≤15 kg, Vedolizumab (Low Dose)

At Week 14, participants who achieve clinical response will be assigned to one of the following groups, stratified by weight to receive vedolizumab 108 mg SC injection during the 20-week Maintenance Period:

  • Participants ≥30 kg, Vedolizumab 108 mg once every 2 weeks (Q2W)
  • Participants ≥10 to \<30 kg, Vedolizumab 108 mg once every 4 weeks (Q4W)

This multi-center trial will be conducted globally. After the Week 34 end of treatment (EOT) visit assessments have been completed, participants may be eligible to receive continued treatment with vedolizumab SC in an extension study, whereas participants who do not qualify to receive continued treatment in the extension study or participants who discontinue from the study for any reason will complete the EOT visit, and the follow-up safety visit (18 weeks after last dose).

03

Conditions studied

  • Ulcerative Colitis
  • Crohn's Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant weighs ≥10 kg at the time of screening and enrollment into the study.
  2. Participants with UC or CD diagnosed at least 1 month before screening. Participants with moderately to severely active disease defined as:

    • Participants with UC: a modified Mayo score of 5 to 9 (sum of Mayo endoscopic subscore, stool frequency subscore, and rectal bleeding subscore) with a Mayo endoscopic subscore of ≥2 (with the presence of mucosal friability excluding an endoscopic subscore of 1 and mandating a score of at least 2). (The results of screening endoscopy should be applied.)
    • Participants with CD: a pediatric Crohn's disease activity index (PCDAI) >30 and a simple endoscopic score for Crohn's disease (SES-CD) >6 (or an SES-CD ≥4 if disease is confined to terminal ileum) at screening endoscopy.
  3. Participants who have failed, lost response to, or been intolerant to treatment with at least 1 of the following agents: , immunomodulators (for example, azathioprine [AZA], 6-mercaptopurine [6-MP], methotrexate [MTX]), and/or tumor necrosis factor (TNF)-α antagonist therapy (for example, infliximab, adalimumab).
  4. Participants with evidence of UC extending proximal to the rectum (that is, not limited to proctitis), at a minimum.
  5. Participants with extensive colitis or pancolitis of >8 years' duration or left-sided colitis of >12 years' duration must have documented evidence of a negative surveillance colonoscopy within 12 months before screening.
  6. Participants with vaccinations that are up-to-date based on the countrywide accepted schedule of childhood vaccines.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have had previous exposure to approved or anti-integrins, including but not limited to, natalizumab, efalizumab, etrolizumab, or abrilumab (AMG 181); or mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antagonists (ontamalimab), or rituximab.
  2. Participants who have had prior exposure to vedolizumab.
  3. Participants with or allergies to vedolizumab or any of its .
  4. Participants with active cerebral/meningeal disease, signs/symptoms or history of progressive multifocal leukoencephalopathy (PML) or any other major neurological disorders.
  5. The participant has received any within 30 days before first dose of study drug.
  6. Participants who currently require surgical intervention or are anticipated to require surgical intervention for UC or CD during this study.
  7. Participants who have had subtotal or total colectomy or have a jejunostomy, ileostomy, colostomy, ileo-anal pouch, known fixed stenosis of the intestine, short bowel syndrome, or >3 small intestine resections.
  8. Participants with a current diagnosis of indeterminate colitis.
  9. Participants with clinical features suggesting monogenic very early-onset inflammatory bowel disease (IBD).
  10. Participants with active or latent tuberculosis (TB).
  11. Participants with evidence of positive surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune subjects (that is, HBsAg negative and hepatitis B surface antibody [anti-HBs]-positive) may, however, be included.
  12. The participant has any identified congenital or acquired immunodeficiency (for example, common variable immunodeficiency, [HIV] infection, organ transplantation).
  13. Participants with positive stool studies for ova and/or parasites or stool culture at screening visit.
  14. Participants with positive Clostridioides difficile (C difficile) stool test at screening visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Induction Period: Participants ≥30 kg, Vedolizumab (High Dose) IV

    Participants weighing ≥30 kg will receive vedolizumab (High Dose) IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.

    Drug: Vedolizumab IV

  • Experimental
    Induction Period: Participants >15 to <30 kg, Vedolizumab (Medium Dose) IV

    Participants weighing \>15 to \<30 kg will receive vedolizumab (Medium Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.

    Drug: Vedolizumab IV

  • Experimental
    Induction Period: Participants ≥10 to ≤15 kg, Vedolizumab (Low Dose) IV

    Participants weighing ≥10 to ≤15 kg will receive vedolizumab (Low Dose), IV infusion, at Day 1, Weeks 2 and 6 in the Induction Period.

    Drug: Vedolizumab IV

  • Experimental
    Maintenance Period: Participants ≥30 kg, Vedolizumab 108 mg SC Q2W

    Participants with clinical response at Week 14 weighing ≥30 kg will receive vedolizumab 108 mg, SC injection, Q2W from Week 14 to Week 32 in the Maintenance Period.

    Drug: Vedolizumab SC

  • Experimental
    Maintenance Period: Participants ≥10 to <30 kg, Vedolizumab 108 mg SC Q4W

    Participants with clinical response at Week 14 weighing ≥10 to \<30 kg will receive vedolizumab 108 mg, SC injection, Q4W from Week 14 to Week 30 in the Maintenance Period.

    Drug: Vedolizumab SC

Interventions

  • Vedolizumab IV injection.

    Also known as: ENTYVIO, KYNTELES, MLN0002

  • Vedolizumab SC injection.

    Also known as: MLN0002SC

06

What researchers measure

Primary outcomes

  1. Ctrough,ss: Steady-state Median Observed Plasma Concentration at the End of a Dosing Interval for Vedolizumab at Week 34

    Time frame: Predose at Week 34

  2. Cavg,ss: Average Serum Concentration at Steady-state for Vedolizumab at Week 34

    Time frame: Multiple time points prior to Week 34; pre-dose at Week 34

Secondary outcomes

  1. Percentage of Participants with Positive Antivedolizumab Antibody (AVA)

    Time frame: Baseline up to 18 weeks after last dose of study drug (up to Week 50)

  2. Percentage of Participants with Positive Neutralizing AVA

    Time frame: Baseline up to 18 weeks after last dose of study drug (up to Week 50)

07

Study locations

26 of 54 sites recruiting
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Not yet recruiting
  • Loma Linda University School of Medicine
    Loma Linda, California 92354, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Hospital Of Orange County
    Orange, California 92868, United States
    Recruiting
    • Site Contact · Contactkgrant@choc.org · 714-509-4099
    • Kenneth Grant · Principal investigator
  • Stanford Children's Health
    Palo Alto, California 94304, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Advocate Children's Hospital
    Park Ridge, Illinois 60068, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
    Recruiting
    • Site Contact · Contactkcares@dmc.org · 313-745-5585
    • Kristen Cares · Principal investigator
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • New York Presbyterian Hospital, Weill Cornell Medical College
    New York, New York 10065, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Penn State Health Milton S. Hershey Medical Center/ Penn State University College of Medicine
    Hershey, Pennsylvania 17033, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Medical University of South Carolina
    North Charleston, South Carolina 29406, United States
    Not yet recruiting
    • Site Contact · Contactsuppa@musc.edu · 843-876-0444
    • Carmine Suppa · Principal investigator
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
    Not yet recruiting
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
    Recruiting
  • Centre Hospitalier Chretien MontLegia
    Liège, 4000, Belgium
    Recruiting
  • University Hospital "Saint George"
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Hvidovre University Hospital
    Hvidovre, Capital Region 2650, Denmark
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Childrens Health Ireland
    Dublin, D12 N512, Ireland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria Gaetano Martino Messina
    Messina, 98124, Italy
    Recruiting
  • V. Buzzi Hospital
    Milan, 20154, Italy
    Recruiting
  • Unita Operativa Complessa Di Pediatria Medica
    Pescara, 65125, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IRCCS Ospedale Pediatrico Bambino Gesu
    Rome, 00165, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Juntendo University Hospital
    Bunkyo-ku, Tokyo 113-8431, Japan
    Recruiting
    • Site Contact · Contactt-kudo@juntendo.ac.jp · +81-3-3813-3111
    • Takahiro Kudo · Principal investigator
  • National Center for Child Health and Development (NCCHD)
    Setagaya-Ku, Tokyo 157-8535, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Radboud University Medical Center
    Nijmegen, 6525 GA, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instytut Pomnik - Centrum Zdrowia Dziecka
    Warsaw, Masovian Voivodeship 04730, Poland
    Recruiting
    • Site Contact · Contactj.kierkus@wipw.waw.pl · 48500111648
    • Jaroslaw Kierkus · Principal investigator
  • Korczowski Bartosz, Gabinet Lekarski
    Rzeszów, 35302, Poland
    Recruiting
    • Site Contact · Contactkorczowski@op.pl · 604481752
    • Bartosz Korczowski · Principal investigator
  • Medical Network Sp. Z.o.o. WIP Warsaw IBD Point Profesor Kierkus
    Warsaw, 04-501, Poland
    Recruiting
  • SPSK Nr 1 im. Prof. S. Szyszko SUM w Katowicach
    Zabrze, 41-800, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Pediatrico - Unidade Local de Saude de Coimbra
    Coimbra, 3000-602, Portugal
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital St Maria- Centro Hospitalar de Lisboa, Norte EPE
    Lisbon, 1649-035, Portugal
    Recruiting
  • Centro Materno Infantil do Norte - Unidade Local de Saude de Santo Antonio
    Porto, 4050-165, Portugal
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • "Emergency County Clinical Hospital ""Pius Brinzeu"""
    Timișoara, Timiș County 300226, Romania
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dr Victor Gomoiu Clinical Children Hospital
    Bucharest, 022102, Romania
    Recruiting
    • Site Contact · Contactif_boian@yahoo.com · 0040725535100
    • Iulia Florentina Tincu · Principal investigator
  • Spitalul Clinic de Urgenta Pentru Copii ,,Grigore Alexandrescu,
    Bucharest, 11743, Romania
    Recruiting
    • Site Contact · Contactcbecheanu@yahoo.com · 40722882898
    • Cristina Becheanu · Principal investigator
  • University Children's Hospital
    Belgrade, 11000, Serbia
    Recruiting
  • Mother and child helath care Institute of Serbia dr Vukan Cupic
    Belgrade, 11070, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institute for Childand YouthHealth Care of Vojvodina
    Novi Sad, 21000, Serbia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kyungpook National University Chilgok Hospital (KNUCH)
    Daegu, 41404, South Korea
    Recruiting
    • Site Contact · Contactbenkang@knu-ac.kr · 82-53-200-3780
    • Ben Kang · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • Site Contact · Contactmjschj@snu.ac.kr · 82220723627
    • Jin Soo Moon · Principal investigator
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
    Recruiting
    • Site Contact · Contactejlee7@yuhs.ac · 82 2 2228 5924
    • Eunjoo Lee · Principal investigator
  • Samsung Medical Center
    Seoul, 06351, South Korea
    Recruiting
  • Complejo Hospitalario Universitario de Ferrol
    Ferrol, 15405, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital U. Virgen Macarena
    Seville, 41009, Spain
    Recruiting
  • Hospital Univesritario y Politecnico La Fe. Av Fernando abril Martorell106. Valencia 46026. Spain
    Valencia, 46026, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Hospitalier Universitaire Vaudois (CHUV)
    Lausanne, Canton of Vaud 1011, Switzerland
    Recruiting
  • Inselspital, Universitatsspital Bern, Kinderklinik, Julie-von-Jenner-Haus
    Bern, 3010, Switzerland
    Recruiting
  • Universitats-Kinderspital
    Zurich, 8008, Switzerland
    Recruiting
  • National Taiwan University Children's Hospital
    Taipei, Zhongzheng Dist 100, Taiwan
    Recruiting
    • Site Contact · Contactwjf@ntu.edu.tw · +886 2 23123456 #271718
    • Jia-Feng Wu · Principal investigator
  • Changhua Christian Hospital
    Changhua, 500010, Taiwan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
    Recruiting
    • Site Contact · Contacthsianghung@gmail.com · +886-0912168512
    • Hsiang-Hung Shih · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for May 2028, 39 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 39 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 25, 2023
StartActual
Jan 22, 2025
Primary completionEst.
May 16, 2028
CompletionEst.
May 16, 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100289
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jan 22, 2025
Primary completion
May 16, 2028 (estimated)
Completion
May 16, 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion